NIKKEI 225
38,923.03 +435.13 (+1.13%) HANG SENG
18,403.04 +323.43 (+1.79%) CRUDE OIL
74.11 -2.88 (-3.74%) GOLD FUTURES
2,369.40 +23.60 (+1.01%) DOW
38,374.49 -311.83 (-0.81%) Bitcoin GBP
54,123.34 +1,040.05 (+1.96%)
SNY Jun 2024 45.000 call
| Previous close | 5.70 |
| Open | 5.70 |
| Bid | 2.80 |
| Ask | 6.60 |
| Strike | 45.00 |
| Expiry date | 2024-06-21 |
| Day's range | 5.70 - 5.70 |
| Contract range | N/A |
| Volume | |
| Open interest | 3 |
BenzingaZantac Heart Burn Continues For GSK As US Court Ruling Allows Thousands Of Zantac Lawsuits To Move Forward
On Monday, GSK Plc (NYSE:GSK) shares were down after the Delaware State Court ruled that more than 70,000 lawsuits could proceed over its discontinued heartburn drug, Zantac (ranitidine). The State Court’s decision contradicts the Federal Court’s Multidistrict Litigation ruling under the same legal standard, which dismissed all cases alleging five cancer types in December 2022. GSK says the litigation in Delaware remains at an early stage, and the ruling, under the Daubert standard, relates only
BloombergGSK Plunges as Drugmaker Must Face Zantac Cases in Delaware
(Bloomberg) -- GSK Plc shares plunged in the wake of a court ruling that the UK drugmaker, alongside others including Sanofi, must face trials over whether the former heartburn treatment Zantac causes cancer. Most Read from BloombergKey Engines of US Consumer Spending Are Losing Steam All at OnceGameStop Shares Surge as Gill’s Reddit Return Shows Huge BetMnuchin Chases Wall Street Glory With His War Chest of Foreign MoneyHomebuyers Are Starting to Revolt Over Steep Prices Across USAMLO Protege S
BenzingaFDA Extends Review Deadline For Regeneron/Sanofi's Dupixent For 'Smoker's Lungs' Disease
On Friday, the FDA extended the target action date of priority review of supplemental application seeking approval for Dupixent (dupilumab) as an add-on maintenance treatment in certain adult patients with uncontrolled chronic obstructive pulmonary disease (COPD), a lung disease that’s usually caused by smoking. The revised target action date is September 27, 2024. The FDA accepted the application in February, with a target action date of June 27, 2024. The FDA did not raise any concerns regardi
